Evolution of Acquired Resistance to Targeted Therapies in Lung Cancer

被引：0
|
作者：
Hata, Aaron N. [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
ONCOLOGIST | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [41] Finding biomarkers of resistance to targeted cancer therapies
    Bernards, Rene
    EJC SUPPLEMENTS, 2007, 5 (05): : 109 - 114
  • [42] Reversing Resistance to Targeted Therapies in Breast Cancer
    Andre, F.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 133 - 133
  • [43] Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
    Delahaye, Celia
    Figarol, Sarah
    Pradines, Anne
    Favre, Gilles
    Mazieres, Julien
    Calvayrac, Olivier
    CANCERS, 2022, 14 (11)
  • [44] Rational design of combination therapies and block of acquired targeted drug resistance
    Reuveni, Hadas
    Kuperschmidt, Lana
    Carmi, Shani
    Moskovitz, Neta
    Stemmer, Salomon
    Haviv, Izhak
    CANCER RESEARCH, 2015, 75
  • [45] Rational design of combination therapies and blockage of acquired targeted drug resistance
    Reuveni, H.
    Kupershmidt, L.
    Carmi, S.
    Moskovitz, N.
    Rozen, M.
    Shlapoberski, M.
    Golomb, E.
    Lotem, M.
    Stemmer, S. M.
    Haviv, I.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S132 - S132
  • [46] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M.
    Trusolino, Livio
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 709 - 722
  • [47] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Simonetta M. Leto
    Livio Trusolino
    Journal of Molecular Medicine, 2014, 92 : 709 - 722
  • [48] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
    Savas, Peter
    Hughes, Brett
    Solomon, Benjamin
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S579 - S592
  • [49] Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
    Annie Roys
    Xing Chang
    Yang Liu
    Xiaobo Xu
    Yingliang Wu
    Daiying Zuo
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 679 - 688
  • [50] Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications
    Joshi, Asim
    Bhaskar, Nivitha
    Pearson, Joel D.
    CANCERS, 2025, 17 (02)
12345